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had gastrointestinal reactions, 3 cases presented with ele-
vated alanine aminotransferase/aspartate aminotransferase 
ratio, and 3 cases had fever. However, all these side effects 
relieved quickly. No elevation of BUN/Cr ratio and aller-
gic reactions was observed. No significant changes in car-
diac function and electrocardiogram were noticed after the 
treatment.
Conclusions Targeted arterial perfusion of verapamil and 
chemotherapeutic drugs can improve the clinical symp-
toms of patients with advanced lung cancer and increase 
the efficacy of chemotherapeutic agents, thereby providing 
an opportunity for radiotherapy or surgical treatment for 
advanced lung cancer.
Keywords Verapamil · Advanced lung cancer · Arterial 
perfusion · Multidrug resistance
Introduction
Lung cancer is one of the most common cancers world-
wide, accounting for 1.2 million new cases annually, and 
the malignancy ranks first in cancer deaths for both men 
and women [1]. Lung cancer has an occult onset and pro-
gresses rapidly. Most of these cases progress to middle or 
advanced stages at definite diagnosis, thereby losing the 
opportunity of surgical treatment [2, 3]. As a consequence, 
adjuvant chemotherapy, notably bronchial arterial infusion 
(BAI), becomes a major approach for clinical treatment for 
lung cancer. BAI can directly infuse high-concentration 
chemotherapeutic agents into tumor tissues, thereby reduc-
ing tumor size, improving clinical symptoms, and decreas-
ing the incidence of adverse effects [4]. However, the natu-
ral or emergence of insensitivity to chemotherapeutic drugs 
in lung cancer during treatment, namely chemotherapy 
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Purpose To assess the clinical efficacy of targeted arterial 
perfusion of verapamil and chemotherapeutic agents in the 
interventional therapy of lung cancer.
Methods Forty patients with advanced lung cancer under-
went treatment with targeted arterial perfusion of verapamil 
and chemotherapeutic agents using Seldinger technique. 
Interventional therapy was performed once a month, and 
each subject received interventional treatment for 2 or more 
cycles. The therapeutic efficacy was evaluated 2 months 
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Results Out of 40 patients with advanced lung cancer, 
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ness (CR + PR) rate of 85 %. Besides, 32 cases achieved 
significantly alleviated clinical symptoms, and 29 cases 
had decreased clinical tumor stage. All subjects had sta-
ble karnofsky performance status score and body weight. 
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resistance, leads to substantially increased failure rates 
in the treatment for lung cancer, with a total efficacy rate 
of 40–60 % [5–7]. Use of effective treatment measures to 
reduce drug resistance in lung cancer and increase the effi-
cacy of chemotherapy is of great significance in improved 
quality of life and prolonged survival in patients with lung 
cancer.
Verapamil is a calcium channel blocker, which is mainly 
indicated for the treatment of heart disease. It has been 
shown that verapamil significantly reverses the multidrug 
resistance (MDR) in tumor cells [8], and the concentration 
of verapamil that can effectively reverse MDR in tumors in 
vitro is 6.0–10.0 μmol/L. Unfortunately, such a concentra-
tion range exceeds the safe concentration (1.0–2.0 μmol/L) 
of verapamil in the peripheral venous blood [9], however, 
intravenous administration of verapamil alone cannot reach 
the concentration large enough to reverse drug resistance. 
In order to reach the concentration capable of reversing 
MDR in tumors and avoid cardiac toxicity, targeted arte-
rial perfusion of verapamil and chemotherapeutic agents 
was performed for tumor chemotherapy. It has been shown 
in animal experiments that the tissue concentration of vera-
pamil infused via the targeted artery is 3–10 times higher 
than the blood concentration [10], and verapamil within a 
safe venous concentration range can reach the concentra-
tion that is capable of reversing drug resistance in tumors. 
Our previous studies showed that targeted arterial infusion 
of verapamil increased the total effectiveness rate to 71.4 % 
and 1-year cumulative survival rate to 81.8 % in patients 
with liver cancer; yet, no cases developed cardiovascular 
toxicity [11, 12]. It is therefore considered that intra-arte-
rial verapamil infusion can not only avoid the emergence 
of disorders of the cardiovascular system caused by drug 
treatment, but also significantly enhance the therapeutic 
efficacy of chemotherapeutic agents in patients with liver 
cancer.
In order to further investigate the improvement of intra-
arterial verapamil infusion in tumor chemotherapy, and 
search for effective chemotherapy of advanced lung cancer, 
interventional therapy with verapamil through the targeted 
arterial infusion was performed for treatment of advanced 
lung cancer, and the clinical efficacy of such a treatment 
regimen in advanced lung cancer was evaluated.
Subjects and methods
Subjects
Forty patients with advanced lung cancer who were admit-
ted to our department during the period from March 
2010 to March 2013 were enrolled in this study. The 
subjects included 33 males and 7 females and were aged 
32–74 years, with a median age of 61 years. Eleven cases 
with squamous cell carcinoma of the lung, 10 cases with 
lung adenocarcinoma, 6 cases moderately differentiated 
squamous cell carcinoma, 5 cases with clinical diagno-
sis of lung cancer, 5 cases with mediastinal lymph node 
metastases from lung cancer, and 3 cases with lung cancer 
complicated by liver metastasis (Table 1). The participants 
involved advanced lung cancer patients with failure in 
standard systemic venous chemotherapy, and some patients 
undergoing interventional therapy in our department for the 
first time. This study was approved by the Ethics Review 
Committee of the hospital. Informed consent was obtained 
from all participants following a detailed description of the 
purpose and potential benefits of the study.
The inclusion criteria involved (1) karnofsky perfor-
mance status (KPS) score ≥70; (2) age range from 18 to 
80 years; (3) life expectancy >3 months; (4) heart rate 
>60 beats/min; (5) patient compliance with the proposed 
regimen, with informed written consent obtained; and (6) 
Table 1  Assessment of 
therapeutic efficacy in 40 cases
Diagnosis Therapeutic efficacy
Cases Efficacy
Total (CR) (PR) (SD) (PD) (CR + PR) %
Squamous cell carcinoma 11 1 7 3 0 72.70
Lung adenocarcinoma 10 2 7 1 0 90.00
Moderately differentiated  
squamous cell carcinoma
6 1 5 0 0 100.00
Clinical diagnosis of lung cancer 5 0 4 0 1 90.00
Mediastinal lymph node  
metastases from lung cancer
5 1 3 1 0 90.00
Lung cancer complicated  
by liver metastasis
3 0 3 0 0 100.00
Total 40 3 31 5 1 85.00
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patients with confirmed diagnoses of lung cancer using 
computed tomography (CT), bronchoscopy, and pathologi-
cal examination, who had no contraindication to the use of 
verapamil, who had tumor lesions that could be used for 
evaluation of therapeutic efficacy, and in whom catheters 
could be inserted into the feeding arteries of the malig-
nant tumor. Subjects who met the following criteria were 
excluded from this study: (1) patients with indications for 
surgery; (2) pregnant or lactating women; (3) patients with 
mental disorders or oligophrenia; (4) patients with acute 
infections or symptoms of the central nervous system; (5) 
patients with a history of allergy; (6) patients with white 
blood cell (WBC) count <4.0 × 109/L; and (7) patients 
with blood coagulation disorders. In addition, patients in 
whom the treatment regimen was not strictly followed, 
those presenting with serious adverse effects who could 
not tolerate the study, or patients with incomplete infor-
mation who presented with difficulty in the assessment of 
side effects and therapeutic efficacy were withdrawn from 
the study.
Interventional treatment method
Interventional therapy was performed once a month, 
and each subject received interventional treatment for 
>2 cycles. Efficacy of the interventional treatment was 
assessed at 2 months post-therapy. In all patients, femoral 
artery was punctured using the Seldinger technique, and 
thoracic aortography was performed via a 5-F pigtail cathe-
ter to observe the arterial blood supply in the lesion region. 
Then, a 5-F cobra catheter was implanted into the bron-
chial arteries that supplied blood for tumors (some were 
branches of the intercostal artery or branches of the internal 
thoracic artery), and perfusion therapy was performed [13].
The chemotherapy regimens were developed according 
to the guidelines for diagnosis and treatment for malignant 
tumors proposed in 2009 annual meeting of the Chinese 
Society of Clinical Oncology of Chinese Anti-cancer Asso-
ciation, including the paclitaxel + cisplatin regimen, the 
docetaxel + cisplatin regimen, the cisplatin and + 5-fluo-
rouracil (5-FU) regimen, and the paclitaxel + gemcit-
abine + 5-FU regimen. The dose of chemotherapeutic 
agents was estimated based on the patients’ body surface 
area and the KPS score.
The perfusion procedures used were as follows: vera-
pamil (15 mg), chemotherapeutic agents, and verapamil 
(10 mg) again. During the perfusion, the catheters were 
intermittently flushed with heparinized saline for 3–5 times. 
Cefoperazone/sulbactam (4.0 g) was infused before and 
after perfusion of chemotherapeutic agents, and ondanse-
tron (8–16 mg) and dexamethasone (5–10 mg) were intra-
venously injected simultaneously. Drug doses were identi-
fied according to tumor size, patients’ general conditions, 
and the heart, liver, and kidney functions. Routine symp-
tomatic treatment was performed after surgery, including 
anti-inflammation, hydration, asthma-relieving treatment, 
and antiemetic therapy.
Clinical observation parameters
Routine blood tests, liver and kidney function tests, and 
electrocardiography (ECG) were performed before treat-
ment and 30 days after treatment, and CT scan was per-
formed before treatment and 30 and 60 days after treat-
ment. Adverse drug reactions, changes in symptoms and 
signs, changes in KPS score, and changes in body weight 
were observed and recorded. The clinical benefit caused 
by 2 cycles of interventional therapy was identified, and 
the presence of new lesions, changes in primary lesions, 
changes in KPS score, and body weight changes were 
observed. Changes in heart rate and blood pressure were 
monitored before, during, and 5 min after perfusion of 
verapamil.
Evaluation of changes in primary lesions
Re-examination with CT scan was performed 3–4 weeks 
after each treatment. The efficacy of antitumor drugs 
against solid tumors was assessed according to the 
response evaluation criteria in solid tumors proposed by 
the European Organization for Research and Treatment 
of Cancer, the US National Cancer Institute (NCI) of the 
National Institutes of Health, and the Canadian Cancer 
Society Research Institute (CCSRI) [14]. Complete remis-
sion (CR): disappearance of all target lesions; partial remis-
sion (PR): at least a 30 % decrease in the sum of the long-
est diameter of target lesion; progressive disease (PD): at 
least a 20 % increase in the sum of the longest diameter of 
target lesions, taking as reference the smallest sum longest 
diameter recorded since the treatment started or the appear-
ance of ≥1 new lesions; stable disease (SD): neither suf-
ficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD.
Identification of clinical benefit
A KPS score increase of >10 which was kept for 4 weeks 
or longer was defined as a positive clinical benefit, while 
a reduction in KPS score was defined as a negative clinical 
benefit; all other outcomes were defined as stable. A body 
weight increase of more than 7 % which was maintained 
for 4 weeks or longer was defined as a positive clinical 
benefit, while a reduction in body weight was defined as a 
negative clinical benefit; all other outcomes were defined as 
stable. To be classified as a clinical responder, a patient had 
to achieve a positive status for at least one of the measures 
892 Cancer Chemother Pharmacol (2013) 72:889–896
1 3
for KPS score or body weight, without being identified as 
negative for the other.
Evaluation of toxicity and cardiac function
Toxicities of the anticancer drugs were assessed accord-
ing to the NCI Common Terminology Criteria for Adverse 
Events (0–IV) [15], and the cardiac function was classified 
using the New York Heart Association Functional Classifi-
cation Criteria (I–IV) [16].
Statistical analysis
All statistical analyses were performed using the statistical 
software Statistical Package for the Social Sciences version 
16.0 (SPSS Inc., Chicago, IL, USA). All measurement data 
were expressed as mean ± SD. Differences of proportions 
were tested for statistical significance with the chi-square 




Each of the 40 cases with advanced lung cancer underwent 
≥2 cycles of interventional treatment with verapamil and 
chemotherapeutic agents, while the changes in primary 
lesions before and after the interventional therapy were 
evaluated using CT scan 2 months after the treatment. The 
results showed CR in 5 cases and PR in 29 cases, with a 
total effectiveness (CR + PR) rate of 85 % (Table 1). In 
addition, 32 cases achieved significantly alleviated clini-
cal symptoms (e.g., chest pain, cough, and expectora-
tion), and 29 cases had decreased clinical tumor stage, 
among which 4 cases got chances of surgery and 25 cases 
of radiation therapy. Notably, following 2 cycles of inter-
ventional therapy with verapamil + paclitaxel + gem-
citabine + 5-FU in our department, the lesion (at a size 
of 2.8 cm × 4.1 cm, Fig. 1a) in the lung of a case with 
adenocarcinoma of the right lung was apparently reduced 
(at a size of 0.5 cm × 0.8 cm, Fig. 1b), and the symptoms 
cough and expectoration disappeared, thereby achieving 
the CR criteria. A patient with moderately differentiated 
squamous cell carcinoma of the left lung complicated by 
right supraclavicular lymph node metastases had a PD after 
1 cycle of intravenous chemotherapy, and the lesion pro-
gressed (at a size of 3.5 cm × 5.2 cm, Fig. 2a) further than 
before (lesion enlargement and presence of pleural effu-
sion). However, the symptoms cough and expectoration 
obviously improved, the lesion in the lung reduced by more 
than 70 % (at a size of 1.1 cm × 1.5 cm, Fig. 2b), and the 
pleural effusion disappeared after 2 cycles of interventional 
treatment and 1 cycle of intrapleural chemotherapy. A 
patient with moderately differentiated adenocarcinoma of 
Fig. 1  CT scan of the patient with adenocarcinoma of the right lung before (a) and after (b) interventional therapy. The arrows showed the posi-
tion of lesions
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the left lung complicated by atelectasis (Fig. 3a) had lung 
recruitment, got surgical treatment, and achieved patho-
logical alleviation after 2 cycles of interventional therapy 
with verapamil + docetaxel + cisplatin in our department 
(Fig. 3b). It is suggested that ≥2 cycles of interventional 
chemotherapy with verapamil and chemotherapeutic agents 
can significantly reduce the size of most primary lesions 
and achieve significantly alleviated clinical symptoms.
Adverse reactions and cardiac function
Of the 40 patients undergoing ≥2 cycles of interven-
tional chemotherapy with verapamil and chemotherapeu-
tic agents, 13 (32.5 %) cases had leucopenia, 10 (25.0 %) 
cases had gastrointestinal reactions, 3 (7.5 %) cases pre-
sented with elevated alanine aminotransferase/aspartate 
aminotransferase ratio, and 2 (5.0 %) cases had fever (body 
temperature, 37.5–39 °C) (Table 2). However, all these side 
effects subsided quickly. No elevation of BUN/Cr ratio or 
allergic reactions was observed. None of the subjects had 
any significant changes in cardiac function before or after 
the interventional treatment (Table 3). In addition, no obvi-
ous changes were detected on ECG (Table 4). The results 
demonstrated that interventional chemotherapy with vera-
pamil and chemotherapeutic agents altered the clinical 
symptoms of the advanced lung cancer patients and did not 
induce severe adverse reactions or cardiac dysfunction.
Discussion
Multidrug resistance is a major cause of diminished clinical 
chemotherapy efficacy of cancer therapies, while abnormal 
cellular efflux pump is a mechanism underlying the emer-
gence of MDR in tumor cells. It is indicated that P-glyco-
protein (P-gp) hydrolyzes ATP to generate ADP and release 
energy and binds to intracellular antitumor drugs with the 
involvement of calcium ions (Ca2+), which pump the anti-
tumor agents out of cells, leading to a reduction in intracel-
lular drug concentration while reducing the efficacy of the 
antitumor agents, resulting in development of MDR [17, 
18]. As a calcium channel antagonist, verapamil is shown 
to inhibit MDR-1 expression and P-gp synthesis, thereby 
increasing the concentration of chemotherapeutic agents in 
tumor cells and overcoming drug resistance in tumor cells 
[19]. Verapamil at a dose of 6–10 μmol/L is shown to com-
pletely inhibit the reversal of MDR by P-gp in malignant 
tumor cells and enhances the sensitivity of tumor cells to 
chemotherapeutic agents [9]. However, verapamil at a 
serum concentration of 1–2 μmol/L may induce adverse 
effects in the cardiovascular system, including a reduced 
heart rate [20], which is a major cause that limits the wide 
application of verapamil as a MDR reversal agent in clini-
cal oncology.
Increased application of interventional radiology 
in diagnosis and treatment for lung cancer, along with 
Fig. 2  CT scan of the patient with moderately differentiated squamous cell carcinoma of the left lung complicated by right supraclavicular 
lymph node metastases before (a) and after (b) interventional therapy. The arrows showed the position of lesions
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improvement of interventional therapeutic techniques, 
has made interventional therapy the major treatment 
for middle-stage and advanced lung cancer. Traditional 
interventional treatments for lung cancer are performed 
through administration of chemotherapeutic agents com-
bined with embolization. These therapies suffer from 
Fig. 3  CT scan of the patient with moderately differentiated adenocarcinoma of the left lung complicated by atelectasis before (a) and after (b) 
interventional therapy. The arrows showed the position of lesions
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problems due to increases in counts of hypoxic cells in the 
target radiotherapy region, leading to a reduction in effi-
cacy of radiotherapy. Transcatheter targeted arterial inter-
ventional therapy can directly infuse high-concentration 
drugs into lesion tissues, which produces high concentra-
tions of chemotherapeutic agents in the tumor tissues, and 
low concentrations in peritumor tissues, as well as other 
unrelated organs and tissues, resulting in extremely low 
systemic adverse effects.
Considering these limitations of the venous concentra-
tion range of verapamil and its high reversal effect on MDR 
in tumors, a series of studies to evaluate the efficacy of tran-
scatheter interventional therapy with verapamil and chemo-
therapeutic drugs have been conducted. It has been found 
in animal experiments that the tissue concentration of vera-
pamil infused via the targeted artery is 3–10 times greater 
than the blood concentration, and targeted arterial infusion 
of verapamil can reverse MDR at a concentration range 
that does not induce cardiac toxicity [10]. Based on these 
exciting findings, we then investigated the clinical efficacy 
of arterial perfusion, transthoracic and intraperitoneal perfu-
sion, and portal venous perfusion of verapamil and chemo-
therapeutic drugs, and high clinical effect was observed in 
advanced liver cancer [12], colon cancer [21], gastric can-
cer, and malignant pleural effusion and ascites [22].
In our study, interventional therapy with verapamil and 
chemotherapeutic drugs through targeted arterial perfusion 
was performed for treatment of middle-stage and advanced 
lung cancer for the first time, and the therapeutic efficacy of 
the interventional treatment was evaluated through assess-
ment of clinical therapeutic efficacy (clinical symptoms and 
cancer size), degree of clinical benefit (KPS score and body 
weight), and adverse reactions (cardiac toxicity, WBC count, 
and gastrointestinal reactions). Our findings showed signifi-
cant alleviation of clinical symptoms in most patients after 
two or more cycles of interventional treatment, with a total 
effectiveness (CR + PR) rate of 85 % (CR in 5 cases and PR 
in 29 cases), and significantly reduced cancer sizes in some 
patients. Following 2 cycles of interventional therapy, the 
lesion in the lung of a case with adenocarcinoma of the left 
lung disappeared, and the lesion in the lung of a patient with 
moderately differentiated squamous cell carcinoma of the 
left lung complicated by right supraclavicular lymph node 
metastases reduced by more than 70 % following interven-
tional therapy. Assessment of clinical benefit revealed sta-
ble KPS scores and body weight in all 40 subjects, while 
no abnormal adverse reactions were observed. None of the 
subjects had any significant changes in cardiac function 
before or after the interventional treatment, and no obvious 
changes were seen on ECG. In addition, no obvious adverse 
reactions of the cardiovascular system were detected. It is 
concluded that targeted arterial perfusion of verapamil and 
chemotherapeutic drugs can improve the clinical symptoms 
of patients with advanced lung cancer, increase the efficacy 
of chemotherapeutic agents, and reduce the clinical tumor 
stage, thereby providing an opportunity for radiotherapy or 
surgical treatment of advanced lung cancer. Further studies 
to investigate the therapeutic efficacy of interventional treat-
ment with verapamil and chemotherapeutic agents in lung 
cancer in larger sample sizes seem justified.
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